7,154 Results

‘Time to Take Action’ on World Bedwetting Day

 Added 11 hours ago

‘Time to Take Action’ on World Bedwetting Day

Now in its 3rd year, the theme for World Bedwetting Day 2017 continues with ‘Time to Take Action’.

Supplemental application for Tresiba (insulin degludec) in hypoglycaemia submitted to FDA- Novo Nordisk

 Added 1 day ago

Novo Nordisk has announced the submission of a supplemental application to the FDA for including data in the label for...

FDA expands approval of Zykadia (ceritinib) to include patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase (ALK)-positive- Novartis

 Added 1 day ago

The FDA has approved the expanded use of Zykadia (ceritinib), from Novartis, to include the first-line treatment of patients with...

Oncologic Drugs Advisory Committee recommends Endari (l-glutamine) to treat sickle cell disease.-Emmaus Life Sciences Inc.

 Added 2 days ago

Emmaus Life Sciences Inc. announced that the Oncologic Drugs Advisory Committee of the FDA voted 10 to 3 that the...

European Commission grants standard marketing approval for Fampyra (prolonged-release fampridine tablets) to improve walking for MS patients on the basis of ENHANCE study.-Biogen

 Added 3 days ago

The European Commission (EC) has granted a standard marketing authorization for Fampyra (prolonged-release fampridine tablets) for walking improvement in people...

Successful Phase III trial of Roclatan (netarsudil/latanoprost ophthalmic solution) to treat glaucoma or ocular hypertension. - Aerie Pharmaceuticals Inc.

 Added 3 days ago

Aerie Pharmaceuticals, Inc. reported the successful primary efficacy results of the Company's 90-day Phase III Mercury 2" registration trial for...

Abilify (aripiprazole) embedded with a Proteus ingestible sensor is re-filed at FDA.- Otsuka + Proteus Digital Health

 Added 4 days ago

Otsuka Pharmaceutical Co., Ltd. and Proteus Digital Health announce that the FDA has acknowledged receipt of the New Drug Application...

EMA widens scope of Zebinix (eslicarbazepine acetate) for use as a once-daily monotherapy to treat adults with newly-diagnosed partial-onset epilepsy. - Bial + Eisai

 Added 4 days ago

The European Medicines Agency has approved the use of Zebinix (eslicarbazepine acetate) from Bial + Eisai for use as a...

NEJM publishes Phase III trial of Epidiolex (cannabidiol) in children with Dravet syndrome. - GW Pharma

 Added 4 days ago

GW Pharmaceuticals plc announced that The New England Journal of Medicine has published results from a Phase III study of...

Bioverativ acquires True North Therapeutics and with it TNT 009 an innovative treatment for cold agglutinin disease.

 Added 5 days ago

Bioverativ Inc. a global biotechnology company which was spun out of Biogen , is focused on the discovery, development and...

Load more